Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients

This study is testing a combination of chemotherapy drugs, an immunotherapy drug (a PD-L1 inhibitor that helps the immune system fight cancer), and a targeted therapy that cuts off the blood supply to tumors, with or without a focused radiation technique (SBRT), as a second-line treatment for advanced pancreatic cancer. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with advanced pancreatic cancer that has spread to other parts of the body - Your cancer has gotten worse after first-line treatment, and that treatment did not include certain chemotherapy drugs (fluorouracil or irinotecan) - Your blood counts and organ function tests are within acceptable ranges **You may NOT be eligible if...** - You have already received second-line or later cancer treatments - Your first-line treatment included fluorouracil, irinotecan, or liposomal irinotecan - You have a history of another cancer (unless it was treated and cured more than 5 years ago) - You have a serious active infection, HIV, hepatitis, or an uncontrolled heart or brain condition - You have an autoimmune disease requiring immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.